Healio8d
FDA receives biologics license application for apitegromab in spinal muscular atrophy
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...
Business Wire1d
LIB Therapeutics Announces FDA Acceptance of Biologics License Application for Lerodalcibep to Lower LDL-Cholesterol Across Broad Patient Population
LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...
Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease
Enveric Biosciences’ (NASDAQ:ENVB) wholly-owned subsidiary, Akos Biosciences, Inc., entered into two licensing agreements ...
Regeneron announces FDA acceptance of BLA for linvoseltamab
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
INmune Bio price target raised to $23 from $22 at Scotiabank
Scotiabank raised the firm’s price target on INmune Bio (INMB) to $23 from $22 and keeps an Outperform rating on the shares. The company’s ...
Managed Healthcare Executive14h
FDA Sets Review Date for Linvoseltamab for Multiple Myeloma
The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...
Benzinga.com7d
Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease
The two licenses grant Restoration Biologics use of the technology for all human and animal applications. Restoration Biologics initially plans to focus on joint pathology, such as osteoarthritis ...
JD Supra5d
Eye-Catching: Biosimilars Injunction Prevails
Cir. Jan. 29, 2025) (Moore, C.J.; Reyna, Taranto, JJ.) Regeneron holds a Biologics License Application for Eylea®, a therapeutic product containing aflibercept (a VEGF antagonist used in various ...
Will gender 'X' be available on NY license? What to know after Trump's order on passports
Many transgender, nonbinary, and intersex Americans now face uncertainty about the status of their passport applications.
Morningstar29d
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of ...